Karolinska Development AB announces the final result in


Karolinska Development AB Announces Final Result of Rights Offering

Karolinska Development AB (“Karolinska Development” or “the Company) capital increase with preferential right for shareholders is completed. the rights number has been subscribed to 76.9 percent and Karolinska Development will thus receive SEK 378 million before transaction costs and loan clearing. The problem advances will be finance the continued development of existing investments, new investments and general corporate objectives. Those who have been allocated shares without the support of the subscription rights will shortly be notified by means of a settlement note or via their nominee.

The subscription period for the rights issue of Karolinska Development with preferential rights for existing shareholders ended on February 2, 2022. In total, the rights issue was subscribed at 76.9%, of which 74.5 % were subscribed with subscription rights and 2.4% without subscription support. rights. No guarantee commitment has been claimed. Karolinska Development thanks existing shareholders for their participation in the rights issue and at the same time welcomes a number of new shareholders, including Swedbank Robur Microcap and Nyenburgh Holding BV

The subscription price for the rights issue was SEK 4.00 per share. Through the rights issue, Karolinska Development will receive SEK 378 million before transaction costs and loan compensation, which primarily funds the company’s continued development of existing investments, new investments and general corporate objectives. .

Shares and share capital

Through the rights issue, the share capital of Karolinska Development is increased by SEK 944,121.85, through the issuance of 1,052,163 class A shares and 93,360,022 class B shares, for a total of 2,700 SEK 775.94 divided into 270,077,594 shares, of which 2,555,261 class A shares and 267,522,333 class B shares.

Translationgo in BTA

The subscribed paid shares (Swedish: Betald tecknad aktie, “BTA”) are traded on Nasdaq Stockholm under the symbol KDEV BTA until the rights issue has been registered with the Swedish Companies Registration Office , which is expected to take place in week 8, 2022.


A notice of allocation of the shares subscribed without the support of the subscription right will be sent shortly to the persons allocated by settlement note. Registered shareholders receive an allocation notification in accordance with the nominee’s respective routines. The allocation of the shares subscribed without maintenance of the subscription right was carried out in accordance with the principles set out in the prospectus published on January 14, 2022.


Erik Penser Bank is financial advisor to Karolinska Development on the rights issue and Cirio Advokatbyrå AB is legal advisor.

For more information, please contact:
Viktor Drvota, VD Karolinska Development
Email: [email protected]

Karolinska Development AB in brief

Karolinska Development is an investment company that offers investors the opportunity to participate in the development of the value of several Nordic life science companies. The Company is focused on identifying medical innovations and invests to create and grow companies that further develop these innovations into differentiated commercial products, which can make a difference in the lives of patients and generate an attractive return for shareholders.


The information contained in this press release does not constitute an offer to acquire, subscribe for or exchange shares, paid subscribed shares, subscription rights or other securities of Karolinska Development. No action has been taken, and no action will be taken, to permit a public offering in any jurisdiction other than Sweden.

The information contained in this press release may not be published or distributed, directly or indirectly, in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “United States States”), Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or South Korea or any jurisdiction where it may be illegal, subject to legal restrictions or require other actions than those prescribed by Swedish law. Actions in violation of these instructions may constitute a violation of applicable securities laws. This press release does not constitute an offer of invitation to acquire or subscribe for shares or other securities in the United States. No shares, subscribed paid shares, subscription rights or other securities issued by the Company (the “Securities”) have been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”). or securities laws in any other state or jurisdiction of the United States and no securities may be offered, subscribed for, used, pledged, sold, retailed, delivered or transferred, directly or indirectly, in the United States. United otherwise than pursuant to an applicable exemption from, or in connection with a transaction not subject to the registration requirements of the Securities Act and in compliance with applicable securities laws of any state or other state jurisdiction -United. The Securities have not been and will not be approved or registered by the Securities and Exchange Commission, any state securities authority or any other authority in the United States. None of these authorities have evaluated or made any representations regarding the Capital Increase or the accuracy or reliability of the prospectus. To claim otherwise is a criminal act in the United States.

This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. In any EEA Member State other than Sweden, this communication is only addressed to and intended solely for “accredited investors” in that Member State within the meaning of the Prospectus Regulation.

In the United Kingdom, this document and any other document relating to the securities described herein are only being distributed and intended for, and any investment or investment activity to which this document relates is available only and will be engaged only with “qualified investors” within the meaning of the Prospectus Regulation who are (i) persons with professional investment experience and who fall within the definition of “investment professionals” in Article 19(5) of the Code of Financial Services and Markets (Financial Promotion) Act 2005 Order 2005 (the “Order”); or (ii) “high net worth entities” falling within section 49(2)(a) to (d) of the Order (all such persons together being referred to as the “Relevant Persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to and will be engaged in only with relevant persons. Persons who are not affected persons should not take any action based on this announcement and should not act or rely on it.

  • Faktiskt emissionsutfall – KD (ENG)

About Wanda Dufresne

Check Also

Karolinska Development’s Portfolio Company Umecrine Cognition Secures Funding Ahead of Phase 2 Study of Golexanolone in Primary Biliary Cholangitis

Karolinska Development AB (publ) STOCKHOLM, SWEDEN – September 14, 2022. Karolinska Development AB (Nasdaq Stockholm: …